Edgar Filing: AGENUS INC - Form 4

AGENUS INC Form 4										
October 05, 2011									PPROVAL	
		STATES		RITIES A shington			E COMMISSIO	N OMB Number:	3235-0287	
Check this box if no longer subject to STATEMENT OF CHANG					BENER RITIES	Expires: Estimated burden hou response	urs per			
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17(a) of the l	Public U	tility Ho	ding Co		nge Act of 1934, t of 1935 or Secti 1940			
(Print or Type Respon	nses)									
1. Name and Address of Reporting Person <u>*</u> DECHAENE TOM			Symbol	er Name an US INC [5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (I	Middle)						eck all applicabl	e)	
C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900			(Month/I 10/03/2	Day/Year) 2011			X_ Director 10% Owner Officer (give title Other (specify below) below)			
()	Street)	4. If Amendment, Date Original Filed(Month/Day/Year)				al	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
NEW YORK, N	Y 10010						Person	More than One K	eporting	
(City) (State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	insaction Date th/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D) Price	(Instr. 3 and 4)			
Reminder: Report on	a separate line	for each cl	ass of secu	urities bene	ficially ow	ned directly	or indirectly.			
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction	orDerivative	Expiration Date	Underlying Securities	
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	

8 E S

Edgar Filing: AGENUS INC - Form 4

(Instr. 3)	Price of (Month/Day/Yo Derivative Security		(Month/Day/Year)	(Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					(1		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Shares (1)	\$ 3.8	10/03/2011		А		756.527		(1)	(1)	Common Stock	756.527

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
DECHAENE TOM C/O ANTIGENICS INC. 162 FIFTH AVENUE, SUITE 900 NEW YORK, NY 10010	Х						
Signatures							
Christine M. Klaskin, by Power of Attorney		10/03/20	011				
**Signature of Reporting Person	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Acquired under the Agenus Inc. Directors' Deferred Compensation Plan, as amended. Deferred Shares represent an equal amount of(1) shares of the Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.